Myriad Genetics

MYGN · NASDAQ

$5.54+$1.33 (+31.59%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $4.21

MYGN analyst rating

HoldConsensus of 9 analysts over the last 12 months. 22% rate it a buy.

Strong buy0
Buy2
Hold6
Underperform1
Sell0

12-month price target · 11 analysts

Average $3.43 (−38.0% downside)

Low: $2.02
Now: $5.54
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

MYGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
TD Cowen	Oct 13, 2026	Maintains	Hold	$4.00 → $4.50	100%
Craig-Hallum	Oct 2, 2026	Maintains	Buy	$4.00 → $8.00	57%
UBS	Sep 9, 2026	Maintains	Neutral	$6.00 → $3.60	86%
Piper Sandler	Sep 1, 2026	Downgrade	Overweight → Underweight	$5.45 → $2.00	58%
Stephens & Co.	Aug 18, 2026	Maintains	Equal-Weight	$5.00 → $3.00	51%
Wells Fargo	Aug 3, 2026	Maintains	Equal-Weight	$5.50 → $3.00	100%
TD Cowen	Jul 31, 2026	Maintains	Hold	$6.00 → $4.00	100%
TD Cowen	May 6, 2026	Maintains	Hold	$7.00 → $6.00	100%
Wells Fargo	May 6, 2026	Maintains	Equal-Weight	$6.00 → $5.50	66%
UBS	Feb 24, 2026	Maintains	Neutral	$8.00 → $6.00	86%

The case for and against

Updated Oct 15, 2026

Bull case

Myriad Genetics is supported by improving underlying demand, with 1Q revenue of $200.4M up 2% year over year and total volume flat, while GeneSight revenue grew more than 20% and HCT volume rose 14%, suggesting its core franchises still have traction. The outlook is further strengthened by management’s FY'26 guidance for $860M-$880M in revenue, implying about 6% growth at the midpoint, alongside 68%-69% adjusted gross margin and $37M-$49M adjusted EBITDA, indicating a path toward better profitability. Positive catalysts also include a more focused and expanded sales force, over 100 added reps, and new product launches such as Precise MRD, Prolaris with PATHOMiQ, and FirstGene, which could accelerate growth into 2H.

Bear case

Myriad Genetics is facing a deteriorating fundamental backdrop because the hoped-for turnaround under new leadership has not translated into sustained operating improvement, with 2Q26 revenue declining low double digits, margins compressing 460 bps year over year, and the company cutting guidance by $90M at the midpoint. Prenatal weakness appears structural rather than temporary, as revenue fell 16% to about $40 million in 2Q26 after a 15% decline in 1Q, while Reproductive Health volume losses and Hereditary Cancer pricing pressure point to share loss, payer friction, and gross-margin erosion. Even though total revenue in 1Q was $200.4 million and gross margin 68.8%, the sub-1x sales valuation reflects worsening operating quality, leaving limited confidence that growth areas like HCT and GeneSight can offset ongoing declines.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.